IDH1 and central nervous system cancer: The EORTC 26053 (CANTON) trial indicated no benefit from concurrent TMZ but showed improved survival with adjuvant TMZ in IDH‐mutant glioma cases, necessitating further investigation into TMZ's optimal use.1, 17